Klox is a private regenerative medicine company, advancing the development of its FLE platform, also known as Fluorescence Biomodulation, for specific skin/soft tissue conditions and diseases. We believe in providing healthcare professionals with novel and effective treatment solutions, which in turn allow patients to experience positive results without extensive side effects or high costs associated with existing stand of care treatments. At present, Klox has 5 series of products, and 12 hard-to-heal indications have been approved by the European Union, the United Kingdom, Canada, Israel, Australia, Singapore and other places. Several products including LumiHeal, Acne Treatment, Skin Rejuvenation, Pre-Post of medical and Aesthetic series have been approved in China.

Technology
FLE provides a unique and dynamic energy output that allows for the stimulation of the mitochondria, the engine of the cells. In the mitochondria, cellular respiration occurs, and energy is created by converting oxygen into ATP. Within all cells, especially within their mitochondria, there are an abundance of photoreceptors, for example, flavins, iron-sulfur or heme centers, which can absorb fluorescence. Data on file shows that triggering FB results in an increase in mitochondrial number and size – this process is known as mitochondrial biogenesis. These dynamic and morphological changes reflect an increase in energy supply.

Business Process
Our products have been widely certified and marketed in 14 countries and regions, including the European Union, the United Kingdom, Canada, Israel, Australia, New Zealand and Singapore, covering more than 1,000 high-end medical beauty institutions.

In June 2021, our products have been approved in China.

Corporate Mission
Maximize and expand the benefits of fluorescence biomodulation, explore new applications and treatment benefits for humans.